Stay updated on Letetresgene Autoleucel+Pembrolizumab in NY-ESO-1+ MM Clinical Trial

Sign up to get notified when there's something new on the Letetresgene Autoleucel+Pembrolizumab in NY-ESO-1+ MM Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Letetresgene Autoleucel+Pembrolizumab in NY-ESO-1+ MM Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    A backend version update shows revision v3.4.3 replacing v3.4.2. No visible changes to study content or user-facing features.
    Difference
    0.0%
    Check dated 2026-03-11T14:43:46.000Z thumbnail image
  2. Check
    9 days ago
    No Change Detected
  3. Check
    16 days ago
    No Change Detected
  4. Check
    31 days ago
    Change Detected
    Summary
    Revision: v3.4.2 is now shown on the page. Notices about government funding lapse and an older Revision: v3.4.1 have been removed.
    Difference
    0.4%
    Check dated 2026-02-11T05:51:28.000Z thumbnail image
  5. Check
    38 days ago
    Change Detected
    Summary
    A government funding lapse notice about site status was added, and the page now displays the updated revision version 3.4.1 (replacing 3.4.0). To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2026-02-04T05:38:36.000Z thumbnail image
  6. Check
    45 days ago
    Change Detected
    Summary
    Added a 'Show glossary' option and updated metadata with 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data' plus a new revision tag 'Revision: v3.4.0', while removing older labels 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and 'Revision: v3.3.4'. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2026-01-28T03:30:41.000Z thumbnail image
  7. Check
    59 days ago
    Change Detected
    Summary
    The page now displays Revision: v3.3.4 instead of v3.3.3. This is a minor version-label update that does not alter trial information or how users interact with the page.
    Difference
    0.0%
    Check dated 2026-01-14T01:18:09.000Z thumbnail image
  8. Check
    80 days ago
    Change Detected
    Summary
    Locations are now presented under a single 'Locations' heading, and the state-specific site details (California, Florida, Georgia, Maryland) have been removed.
    Difference
    0.5%
    Check dated 2025-12-23T08:49:00.000Z thumbnail image

Stay in the know with updates to Letetresgene Autoleucel+Pembrolizumab in NY-ESO-1+ MM Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Letetresgene Autoleucel+Pembrolizumab in NY-ESO-1+ MM Clinical Trial page.